Published in Prostaglandins Leukot Essent Fatty Acids on January 01, 1996
Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A (1998) 1.74
Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol (2001) 1.34
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci (2007) 1.03
Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis (2002) 1.01
Stress-responsive JNK mitogen-activated protein kinase mediates aspirin-induced suppression of B16 melanoma cellular proliferation. Br J Pharmacol (2003) 0.90
Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. Br J Cancer (2002) 0.84
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. J Laryngol Otol (2009) 0.84
Cytotoxic effect of HIV-1 coat glycoprotein gp120 on human neuroblastoma CHP100 cells involves activation of the arachidonate cascade. Biochem J (1998) 0.82
White tea extract induces apoptosis in non-small cell lung cancer cells: the role of peroxisome proliferator-activated receptor-{gamma} and 15-lipoxygenases. Cancer Prev Res (Phila) (2010) 0.80
Chemopreventive effect of montelukast in n-nitroso n-methyl urea induced mammary carcinogenesis in female Sprague-Dawley rats. Indian J Pharmacol (2013) 0.79
Mitochondria-mediated ATP depletion by anti-cancer agents of the jasmonate family. J Bioenerg Biomembr (2007) 0.77
Oxymetry deep in tissues with low-frequency electron paramagnetic resonance. Proc Natl Acad Sci U S A (1994) 2.53
A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol (1992) 2.10
Overexpression of metallothionein confers resistance to anticancer drugs. Science (1988) 2.03
Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res (1981) 1.91
Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A (1993) 1.63
Retracted A phase I-II trial of cisplatin, hyperthermia and radiation in patients with locally advanced malignancies. Int J Radiat Oncol Biol Phys (1989) 1.43
The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol (1980) 1.24
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res (1987) 1.23
Measurement of differences in pO2 in response to perfluorocarbon/carbogen in FSa and NFSa murine fibrosarcomas with low-frequency electron paramagnetic resonance oximetry. Radiat Res (1996) 1.21
Diminished aqueous microviscosity of tumors in murine models measured with in vivo radiofrequency electron paramagnetic resonance. Cancer Res (1999) 1.16
Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res (1986) 1.15
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs (1997) 1.12
Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res (1981) 1.12
Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res (1988) 1.10
Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem (1990) 1.00
Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst (1992) 0.98
Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. Int J Hyperthermia (2001) 0.96
A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res (1991) 0.94
Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood (1996) 0.94
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol (1990) 0.94
Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker. J Surg Oncol (1997) 0.93
Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int J Radiat Oncol Biol Phys (1997) 0.93
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol (1998) 0.92
Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol (2000) 0.91
Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cells. Mol Carcinog (1991) 0.89
Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance. Cancer Res (1989) 0.88
Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hyperthermia (1988) 0.88
Radiosensitization of EMT6 cells by four platinum complexes. Int J Radiat Oncol Biol Phys (1985) 0.87
Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr Pharm Des (2001) 0.87
Effect of hyperthermia on cis-diamminedichloroplatinum(II) (rhodamine 123)2[tetrachloroplatinum(II)] in a human squamous cell carcinoma line and a cis-diamminedichloroplatinum(II)-resistant subline. Cancer Res (1988) 0.87
Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. J Biol Chem (1993) 0.86
Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res (1996) 0.86
Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int J Cancer (1993) 0.86
Perfluorochemical emulsions can increase tumor radiosensitivity. Science (1984) 0.86
Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin. Radiat Res (1997) 0.85
Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood (1995) 0.84
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol (1998) 0.83
Effect of hyperthermia on the action of cis-diamminedichloroplatinum(II), rhodamine 123(2) [tetrachloroplatinum(II)], rhodamine 123, and potassium tetrachloroplatinate in vitro and in vivo. Cancer Res (1988) 0.83
Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int J Hyperthermia (1995) 0.82
Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents. Cancer Res (1989) 0.82
Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice. Cancer Res (1984) 0.82
Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res (1987) 0.82
Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. Br J Cancer (1999) 0.82
Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol Cell Biochem (1990) 0.82
Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents. J Med Chem (1980) 0.82
Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo. Cancer Res (1990) 0.82
Local hyperthermia, radiation therapy, and chemotherapy in patients with local-regional recurrence of breast carcinoma. Int J Radiat Oncol Biol Phys (1993) 0.82
Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol (1989) 0.82
2-Methylanthraquinone derivatives as potential bioreductive alkylating agents. J Med Chem (1980) 0.82
Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures. Cancer Res (1988) 0.81
Antitumor and radiosensitizing activity of several platinum-(+) dye complexes. Radiat Res (1987) 0.81
Subcellular distribution of various boron compounds and implications for their efficacy in boron neutron capture therapy by Monte Carlo simulations. Radiat Res (1993) 0.80
Increased tumor oxygenation and radiation sensitivity in two rat tumors by a hemoglobin-based, oxygen-carrying preparation. Artif Cells Blood Substit Immobil Biotechnol (1995) 0.80
Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents. Cancer Chemother Pharmacol (2000) 0.80
Effect of DNA conformation on cisplatin adduct formation. Biochem Pharmacol (1996) 0.80
Intracellular distribution of a platinum-rhodamine 123 complex in cis-platinum sensitive and resistant human squamous carcinoma cell lines. Biochem Pharmacol (1986) 0.80
Effect of heat on the cytotoxicity and interaction with DNA of a series of platinum complexes. Int J Radiat Oncol Biol Phys (1989) 0.80
Analogues of N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine (PT523) modified in the side chain: synthesis and biological evaluation. J Med Chem (1997) 0.80
Effect of oxygen on the cytotoxicity and antitumor activity of etoposide. J Natl Cancer Inst (1985) 0.79
Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis. Oncol Res (1996) 0.79
cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement. Cancer Res (1994) 0.79
Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation. Int J Hyperthermia (2001) 0.79
Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemother Pharmacol (1995) 0.79
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine. Cancer Chemother Pharmacol (1993) 0.79
DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res (1995) 0.79
Modulation of antitumor alkylating agents (AA). Cancer Treat Res (1991) 0.79
Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells. Anticancer Res (1997) 0.79
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol (2001) 0.78
Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes. Br J Cancer (1985) 0.78
Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol (1992) 0.78
Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation. Radiother Oncol (1990) 0.78
Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J Clin Invest (1987) 0.78
Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo. Int J Cancer (1991) 0.78
Platinum complexes inhibit repair of potentially lethal damage following bleomycin treatment. Br J Cancer (1987) 0.78
Effects of adrenal steroid activator protein on the conversion of various 20- and 22-hydroxycholesterols to pregnenolone by adrenal mitochondrial enzymes. Biochem Biophys Res Commun (1978) 0.78
Effects of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DA. Int J Radiat Oncol Biol Phys (1986) 0.78
Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells. Cancer Chemother Pharmacol (2001) 0.77
Trimodality therapy (drug/hyperthermia/radiation) with BCNU or mitomycin C. Int J Radiat Oncol Biol Phys (1990) 0.77
Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light. Photochem Photobiol (1992) 0.77
Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline. Cancer Chemother Pharmacol (1990) 0.77
Sequencing of trimodality therapy [cis-diamminedichloroplatinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcoma. Cancer Res (1988) 0.77
Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants. Cancer Chemother Pharmacol (1997) 0.77
Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II). Cancer Res (1987) 0.77
Microtubule stabilization and potentiation of taxol activity by the creatine analog cyclocreatine. Anticancer Drugs (1995) 0.77
Differences in in vivo and in vitro sequence-specific sites of cisplatin-DNA adduct formation and detection of a dose-response relationship. Biochem Pharmacol (1994) 0.77
Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity. Cancer Res (1987) 0.77
Interaction with hyperthermia of tetrachloroplatinum(II)(Nile blue)2 and tetrachloroplatinum(II)(neutral red)2 in EMT6 murine cells and the murine FSaIIC fibrosarcoma. Cancer Res (1990) 0.77
Detection of sequence-specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient. Cancer Res (1994) 0.76
Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin. Cancer Chemother Pharmacol (1995) 0.76
Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype. Cancer Biochem Biophys (1998) 0.76
Efficacy of Pt(Rh-123)2 as a radiosensitizer with fractionated X rays. Int J Radiat Oncol Biol Phys (1987) 0.76
Postlabeling detection of DNA adducts of antitumor alkylating agents. Cancer Chemother Pharmacol (1996) 0.76
Some complexes of cobalt(III) and iron(III) are radiosensitizers of hypoxic EMT6 cells. Radiat Res (1987) 0.76
Intracellular distribution of various boron compounds for use in boron neutron capture therapy. Biochem Pharmacol (1993) 0.76
Perfluorochemical emulsions: oxygen breathing in radiation sensitization and chemotherapy modulation. Important Adv Oncol (1992) 0.76
Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells. Cancer Lett (1991) 0.76
Antitumor activity of cryptophycins: effect of infusion time and combination studies. Cancer Chemother Pharmacol (2000) 0.75
Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism. In Vivo (1998) 0.75